Bio


I focus on making Americans healthier through better systems, better policy, and better innovation. I’ve worked alongside academics, clinicians, policymakers, engineers, and entrepreneurs, and I have seen strong reforms stall and promising innovations falter when incentives are misaligned. I believe meaningful healthcare reform in America is possible, but only through coordinated effort across these historically entrenched groups. My work centers on finding bold ideas that challenge the status quo, bringing the right people, institutions, and perspectives together to pressure-test them, and translating the strongest into real-world impact and meaningfully better healthcare for all Americans.

Outside of work, you can usually find me lifting weights, cooking, making coffee, or catching a movie. Always happy to connect and chat.

Honors & Awards


  • Community Impact Award, Stanford Alumni Association (June 2024)
  • Fall Bakeoff Champion, Stanford Health Policy Department (November 2023)
  • Presidential Service Award, University of Florida (April 2022)
  • Truman Scholarship Finalist, The Harry S. Truman Scholarship Foundation (February 2021)

Education & Certifications


  • Policy Fellow, Stanford University, Stanford Biodesign (2025)
  • MS, Stanford University, Health Economics (2024)
  • BS, University of Florida, Biochemistry (2022)

All Publications


  • Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dickerson, J. C., Moen, M. T., Nielsen, P., Riaz, F., Tran, E., Caswell-Jin, J. L., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F. 2025: JCO2401960

    Abstract

    Creating value-aligned treatment pathways in breast cancer requires understanding the cost and cost-effectiveness of new therapies. To address uncertainty in the optimal treatment sequence, we developed a decision model to assess the cost-effectiveness of various treatment sequences for patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer who are eligible for trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) under current US Food and Drug Administration labeling.We derived disease progression and therapy data from the Destiny-Breast04 trial and sourced cost and quality-of-life data from the published literature. Our simulation modeled 57-year-old women with HER2-low, endocrine refractory, and triple-negative metastatic breast cancer eligible for third-line treatment. We evaluated four sequences: chemotherapy (chemo) → chemo, T-DXd → chemo, chemo → T-DXd, and T-DXd → SG. Outcomes included quality-adjusted life years (QALYs), total lifetime costs (2020 US dollars [USD], 3% annual discount), and incremental cost-effectiveness ratios. Sequences that cost <$150,000 USD to gain an additional QALY were considered cost effective.Chemo → chemo has the lowest cost at $176,000 (USD) per patient and yields 0.82 QALYs. T-DXd → chemo costs $282,000 (USD) and yields 1.08 QALYs, with an incremental cost-effectiveness ratio of $408,000 (USD) per QALY gained. T-DXd → SG costs $304,000 (USD) and yields 1.09 QALYs, with an incremental cost-effectiveness ratio of $2,200,000 (USD) per QALY gained. Drug cost drives the cost differences between each strategy. For T-DXd → chemo to be cost effective at the $150,000 (USD) per QALY threshold, we estimate that a 41% price reduction for T-DXd is needed.At its current price, T-DXd is not cost effective for HER2-low metastatic breast cancer. Price reductions can make this drug cost effective. Optimal value-based sequencing in this patient population uses a single antibody-drug conjugate rather than back-to-back conjugates.

    View details for DOI 10.1200/JCO-24-01960

    View details for PubMedID 40397834

  • TEAM-BASED PEDIATRIC T1D CARE: A COSTEFFECTIVENESS ANALYSIS Dupenloup, P., Nielsen, P., Prahalad, P., Zaharieva, D., Maahs, D., Scheinker, D. MARY ANN LIEBERT, INC. 2024: A356
  • AI Alone Will Not Reduce the Administrative Burden of Health Care. JAMA Schulman, K. A., Nielsen, P. K., Patel, K. 2023

    View details for DOI 10.1001/jama.2023.23809

    View details for PubMedID 37971721

  • Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer Dickerson, J., Moen, M., Nielsen, P., Tran, E., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F. LIPPINCOTT WILLIAMS & WILKINS. 2023
  • Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer Dickerson, J., Moen, M., Nielsen, P., Tran, E., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F. LIPPINCOTT WILLIAMS & WILKINS. 2023